Hanx Biopharmaceuticals (HKG:3378) booked 131 million yuan in attributable loss for 2025, widening from a loss of 115.8 million yuan in 2024, according to a Hong Kong bourse filing Friday.
Loss per share was 1.11 yuan, compared with 0.98 yuan in the prior year.
Other income and gains amounted to 16.6 million yuan, rising from 7.7 million yuan in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments